Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

INTRODUCTION: Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rombach, Saskia M., Aerts, Johannes M. F. G., Poorthuis, Ben J. H. M., Groener, Johanna E. M., Donker-Koopman, Wilma, Hendriks, Erik, Mirzaian, Mina, Kuiper, Sijmen, Wijburg, Frits A., Hollak, Carla E. M., Linthorst, Gabor E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477102/
https://www.ncbi.nlm.nih.gov/pubmed/23094092
http://dx.doi.org/10.1371/journal.pone.0047805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477102/
https://www.ncbi.nlm.nih.gov/pubmed/23094092
http://dx.doi.org/10.1371/journal.pone.0047805

Ejemplares similares